Saturday 17 October 2026
Export PEN’s income statement to Excel — free account
Penumbra, Inc.
PEN Healthcare Medical Devices
Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024. In the quarter to June 2026, revenue grew 14.9%, EPS fell 24.8%, free cash flow grew 10.8% and total debt fell 9.90%, each against the same quarter a year earlier. Revenue growth for ten consecutive years, operating cash flow growth for three.
320.86
0.34
−0.11%
Follow PEN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
77.20 | 74.97 | 68.03 | 59.75 |
+8 more quarters Free account |
P/S ratio |
8.26 | 8.87 | 8.62 | 7.42 | |
P/FCF ratio |
57.55 | 60.62 | 69.17 | 64.86 | |
P/Operating CF |
269.64 | 148.29 | 139.91 | 169.91 | |
P/B ratio |
8.12 | 8.75 | 8.48 | 7.29 | |
Price to Tangible BV |
9.15 | 9.91 | 9.64 | 8.35 | |
EV/Sales |
7.83 | 8.46 | 8.25 | 7.09 | |
EV/EBITDA |
57.64 | 60.25 | 56.00 | 49.69 | |
EV/Operating CF |
42.43 | 44.46 | 48.50 | 46.49 | |
EV/FCF |
54.59 | 57.83 | 66.17 | 61.92 | |
Quick Ratio |
3.63 | 3.77 | 4.01 | 3.85 | |
Current Ratio |
5.75 | 6.02 | 6.64 | 6.73 | |
Net Debt/EBITDA |
(13.70) | (13.91) | (8.23) | (8.75) | |
Debt/Assets |
0.99% | 1.07% | 1.13% | 1.22% | |
Debt/Equity |
0.01 | 0.01 | 0.01 | 0.02 | |
Asset Turnover |
0.82 | 0.83 | 0.84 | 0.83 | |
Operating CF/Net income |
1.32 | 2.67 | 1.83 | 1.27 | |
Capex/Depreciation |
(2.41) | (2.99) | (4.13) | (6.53) | |
Research and Development Expense of Revenue |
6.51% | 5.97% | 5.66% | 6.39% | |
Selling, General and Administrative Expense of Revenue |
50.89% | 51.45% | 46.99% | 47.62% | |
Intangible Assets out of Total Assets |
0.09 | 0.09 | 0.09 | 0.10 | |
Share Based Compensation of Revenue |
3.50% | 3.91% | 3.96% | 4.49% | |
Graham Net Nets |
0.07 | 0.07 | 0.07 | 0.08 | |
Graham Number |
59.83 | 60.81 | 61.42 | 57.59 | |
Earnings Yield |
1.30% | 1.33% | 1.47% | 1.67% | |
Free Cash Flow Yield |
1.74% | 1.65% | 1.45% | 1.54% | |
Revenue per Share |
9.91 | 9.54 | 9.90 | 9.08 | |
Operating CF per Share |
1.17 | 2.21 | 2.22 | 1.49 | |
Capex per Share |
(0.34) | (0.35) | (0.47) | (0.42) | |
Free Cash Flow per Share |
0.83 | 1.87 | 1.75 | 1.08 | |
Cash per Share |
16.74 | 15.68 | 14.00 | 12.03 | |
Shareholders Equity per Share |
38.90 | 37.53 | 36.68 | 34.77 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
38.90 | 37.53 | 36.68 | 34.77 | |
Free Cash Flow |
32.54 | 73.30 | 68.05 | 42.01 | |
Working Capital |
1,110.35 | 1,063.68 | 1,033.55 | 971.92 | |
Capital Expenditures |
(13.54) | (13.67) | (18.43) | (16.25) | |
Net Current Asset Value |
900.17 | 850.78 | 817.77 | 755.85 | |
EV/EBIT |
62.92 | 65.74 | 61.17 | 54.69 | |
Capex to Sales |
0.03 | 0.04 | 0.05 | 0.05 | |
Price to Operating Income |
66.33 | 68.92 | 63.94 | 57.29 | |
| Other line items | |||||
Average Receivables |
182.97 | 175.64 | 178.84 | 179.74 | |
Average Payables |
36.42 | 37.41 | 33.03 | 31.49 | |
Average Inventory |
435.14 | 427.20 | 419.14 | 412.89 | |
Average Assets |
1,824.77 | 1,745.87 | 1,679.85 | 1,611.75 | |
Average Common Equity |
1,412.36 | 1,343.35 | 1,289.27 | 1,231.49 |
Columns are period end dates